Aviad A D, Houpt J B
Rheumatic Disease Unit, Mount Sinai Hospital, University of Toronto, ON, Canada.
J Rheumatol. 1994 Feb;21(2):297-301.
Various molecular weight hyaluronic acid (HA) preparations have been injected into joints for the treatment of human and equine osteoarthritis. A therapeutic advantage has been claimed for commercial products with a molecular weight in the range found in normal synovial fluid (SF), compared to lower molecular weight products. But a correlation between molecular weight and efficacy is not borne out by an analysis of the available literature on clinical results. SF viscosity, HA concentration, HA molecular weight and rate of synthesis in joint disease. It is proposed that the beneficial effect of injected HA in joint disease may be due to pharmacological rather than to physical properties.
各种分子量的透明质酸（HA）制剂已被注射到关节中，用于治疗人类和马的骨关节炎。与低分子量产品相比，有人声称分子量在正常滑液（SF）中发现的范围内的商业产品具有治疗优势。但对现有临床结果文献的分析并未证实分子量与疗效之间的相关性。关节疾病中的滑液粘度、HA浓度、HA分子量和合成速率。有人提出，注射HA在关节疾病中的有益作用可能归因于药理性质而非物理性质。
